Activated protein C for the treatment of severe sepsis
- 1 April 2009
- journal article
- review article
- Published by Elsevier BV in Clinical Microbiology & Infection
- Vol. 15 (4), 319-324
- https://doi.org/10.1111/j.1469-0691.2009.02751.x
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Advances in pathogenesis and management of sepsisCurrent Opinion in Infectious Diseases, 2007
- Decrease in circulating dendritic cells predicts fatal outcome in septic shockIntensive Care Medicine, 2006
- Accelerated Lymphocyte Death in Sepsis Occurs by both the Death Receptor and Mitochondrial PathwaysThe Journal of Immunology, 2005
- The Epidemiology of Sepsis in the United States from 1979 through 2000New England Journal of Medicine, 2003
- Early Circulating Lymphocyte Apoptosis in Human Septic Shock Is Associated with Poor OutcomeShock, 2002
- Risks and Benefits of Activated Protein C Treatment for Severe SepsisNew England Journal of Medicine, 2002
- SEPSIS SYNDROMES: UNDERSTANDING THE ROLE OF INNATE AND ACQUIRED IMMUNITYShock, 2001
- Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of careCritical Care Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Long-term health-related quality of life in survivors of sepsis. Short Form 36: A valid and reliable measure of health-related quality of lifeCritical Care Medicine, 2000